What is ARGX stock price today?

ARGX (Argenx Se) stock is trading at $684.77 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ARGX stock going up or down today?

ARGX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ARGX stock now?

The decision to buy ARGX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ARGX a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ARGX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ARGX stock overvalued or undervalued?

ARGX currently trades at a P/E ratio of 36.10, which may indicate premium valuation. Our DCF calculator provides intrinsic value estimates to help determine if ARGX is fairly priced.

What is ARGX's P/E ratio?

ARGX has a price-to-earnings (P/E) ratio of 36.10, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is ARGX's market cap?

ARGX (Argenx Se) has a market capitalization of $43.69 billion, making it a mid-cap stock.

What is ARGX's price to book ratio?

ARGX trades at a price-to-book (P/B) ratio of 5.97, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ARGX pay dividends?

ARGX does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ARGX's dividend yield?

ARGX does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ARGX stock a good long-term investment?

ARGX's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ARGX's revenue growth rate?

ARGX has shown revenue growth of 0.7% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, ARGX is profitable with a profit margin of 0.3%. This indicates the company generates 0.3 cents of profit for every dollar of revenue.

What are the risks of investing in ARGX?

Key risks for ARGX include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ARGX compare to its competitors?

Compare ARGX to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ARGX's performance and positioning.

What is ARGX's stock price target for 2026?

Our AI model provides price targets for ARGX based on fundamental analysis: Bull case $890.20 (+30%), Base case $787.49 (+15%), Bear case $616.29 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ARGX?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ARGX. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ARGX's next earnings report?

ARGX reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ARGX - Argenx Se

NYSE * Health Care * Biotechnology

$684.77

$-21.26 (-3.01%)

About Argenx Se

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

ARGX Key Statistics

Market Cap

$43.69B

P/E Ratio

36.10

P/B Ratio

5.97

EPS

$19.56

Revenue Growth

+0.7%

Profit Margin

0.3%

Employees

1,599

How ARGX Compares to Peers

ARGX trades at a premium valuation vs peers (highest P/E)

ARGX has the fastest revenue growth among competitors

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ARGX(This stock)	$43.69B	36.1	1%	0.3%	-
AMGNAmgen Inc	$194.67B	25.4	0%	0.2%	vs AMGN
GILDGilead Sciences	$179.26B	21.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$117.47B	30.2	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$80.25B	18.3	0%	0.3%	vs REGN
BIIBBiogen Inc	$27.19B	21.1	-0%	0.1%	vs BIIB

Argenx Se Company Information

Headquarters: Belgium
Website: argenx.com
Sector: Health Care
Industry: Biotechnology

About Argenx Se

ARGX Key Statistics

How ARGX Compares to Peers

Argenx Se Company Information

Upcoming Events for ARGX